RecruitingNANCT06836284

Evaluation of a Digital Treatment Tool in Combination With Obesity Medications

Sponsor: Karolinska Institutet

Trial Details

ConditionChildhood Obesity, Treatment Adherence
InterventionDigi-physical treatment tool, Evira; Obesity medication with liraglutide or semaglutide
PhaseNA
StatusRecruiting
Participants40
Est. Completion1 Apr 2027
Last Updated5 May 2026

Primary Outcome

Change in BMI SDS

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * Patients offered liraglutide or semaglutide in accordance with the clinic's routines. * Aged 12-17 years at the time of inclusion. * The family agrees to participate in a clinical study. Exclusion Criteria: * Endocrine disorders other than well-controlled hypothyroidism. * Severe neuropsychiatric disorders that may affect adherence to the study. * Eating disorder requiring treatment within the last six months before inclusion or observed during screening prior to inclusion. * Somatic conditions that may complicate the evaluation of treatment outcomes, such as patients on irregular oral corticosteroid treatment. * Hypothalamic or monogenic obesity, and genetic syndromes such as Down syndrome. * Patients deemed unsuitable for participation by the responsible physician.

Trial Sites

Countries

Sweden
View Registry Entry

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service